Drugs /

gi-6301

Back to Drugs List

Overview

NCI Definition [1]:
A cancer vaccine composed of a heat-killed, recombinant form of the yeast Saccharomyces cerevisiae that is genetically modified to express the transcription factor brachyury protein, with potential antineoplastic activity. Upon subcutaneous administration, the brachyury-expressing yeast vaccine GI-6301 is recognized by dendritic cells, processed, and presented by Class I and II MHC molecules on the dendritic cell surface. This elicits a targeted CD4+ and CD8+ T-lymphocyte-mediated immune response. This process kills brachyury-expressing tumor cells. Brachyury is overexpressed in a variety of tumor types and plays an important role in cancer progression and metastasis.

Clinical Trials

View Clinical Trials for gi-6301

Gi-6301 has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating gi-6301, 1 is phase 2 (0 open).

ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for gi-6301 clinical trials.

Breast carcinoma is the most common disease being investigated in gi-6301 clinical trials [2].

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Gi-6301
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating gi-6301 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
brachyury-expressing yeast vaccine gi-6301
NCIT ID [1]:
C106267

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.